On The Fly: What to watch in Salesforce earnings report
Salesforce (CRM) is scheduled to report results of its third fiscal quarter after the market close on Tuesday, November 21, with a conference call scheduled...
Author : The Fly
Deutsche Bank cuts target on Sell-rated GE to Street-low $15
Deutsche Bank analyst John Inch believes General Electric should trade at a valuation discount given its "still aggressive" accounting, cash flow and debt pressures, and...
Muddy Waters says Alibaba numbers ‘obviously fake’
Short seller Muddy Waters Research just tweeted, "Entertaining and coherent dissection of how obviously fake $BABA's numbers are. Points out Singles Day claimed GMV exceeds...
Cardinal Health slides as Morgan Stanley says sell on Amazon risk
Shares of Cardinal Health (CAH) are sliding after Morgan Stanley analyst Ricky Goldwasser downgraded the stock to Underweight, a sell-equivalent rating, as he believes Amazon...
Nebraska approves TransCanada’s Keystone XL pipeline
The Nebraska Public Service Commission, by a vote of three-to-two, approved an order giving TransCanada the go ahead to build the Keystone XL Pipeline. The...
Standpoint raises 2018 bitcoin price target to $14,000 from $11,000
Standpoint Research analyst Ronnie Moas raised his 2018 price target for bitcoin to $14,000 from $11,000. The price just crossed $8,180 and is now split-adjusted...
Bitcoin hits record high amid Square inclusion on Cash app
Bitcoin hit a new record high on Sunday, breaking the $8,000 threshold for the first time. WHAT'S NEW: Bitcoin reached $8,121.56 on Monday at 12:25...
On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Verizon (VZ) upgraded to Outperform from Market Perform at...
Celgene shares can rebound to $125 in 12-18 months, says Jefferies
After hosting investor meetings with management, Jefferies analyst Michael Yee is more positive on his view that Celgene (CELG) shares can rebound to $125 over...
DBV Technologies says Phase III Realise trial met primary objective
DBV Technologies announced "positive" topline results from the Phase III Realise trial. The double-blinded period compared the safety of treatment with Viaskin Peanut versus placebo...